Cargando…

Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting

BACKGROUND: Remdesivir (RDV) is an intravenous antiviral with activity against SARS-CoV-2 for treatment of hospitalized COVID-19 patients with moderate-to-severe disease. Biomarkers associated with clinical outcomes have been identified for COVID-19, but few evaluated in context of antiviral treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, David Z., Odorizzi, Pamela M., Schoenichen, Andre, Abdelghany, Mazin, Chen, Shuguang, Osinusi, Anu, Patterson, Scott D., Downie, Bryan, Juneja, Kavita, Wallin, Jeffrey J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809529/ https://www.ncbi.nlm.nih.gov/pubmed/36596885 http://dx.doi.org/10.1038/s43856-022-00232-2

Ejemplares similares

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
por: Gottlieb, Robert L., et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study
por: Brown, Samuel M., et al.
Publicado: (2023)

550. Effectiveness of Remdesivir for Treatment of COVID-19 in the Outpatient Setting
por: Vo, Vinny P, et al.
Publicado: (2023)

524. Hepatic Safety of Remdesivir Across Phase 3 Placebo-controlled COVID-19 Studies
por: Force, Lindsey, et al.
Publicado: (2023)

LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Hill, Joshua A, et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
por: Humeniuk, Rita, et al.
Publicado: (2020)

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
por: Murakami, Eisuke, et al.
Publicado: (2021)

Remdesivir for Outpatient Management: Time to Wait, Not to Act
por: Mohapatra, Prasanta Raghab
Publicado: (2022)

Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States
por: Chokkalingam, Anand P., et al.
Publicado: (2022)

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
por: Humeniuk, Rita, et al.
Publicado: (2021)

476. Gilead Sciences’ Commitment to the COVID-19 Pandemic
por: Lee, EunYoung, et al.
Publicado: (2020)

Remdesivir for the Treatment of Covid-19 — Final Report
por: Beigel, John H., et al.
Publicado: (2020)

524. Assessing the Safety of an Outpatient Remdesivir Infusion Program for Patients with Severe COVID-19 in the Setting of a Pandemic Surge
por: Gee, Benjamin, et al.
Publicado: (2021)

544. Outpatient Remdesivir Use at a Stand Alone Children's Hospital
por: Rodriguez, Brittany, et al.
Publicado: (2023)

72. Remdesivir vs Standard Care in Patients with Moderate covid-19
por: Marty, Francisco M, et al.
Publicado: (2020)

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
por: Goldman, Jason D., et al.
Publicado: (2020)

561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19
por: Criner, Gerard J, et al.
Publicado: (2020)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

Remdesivir Use in the Real-World Setting: An Overview of Available Evidence
por: Akinosoglou, Karolina, et al.
Publicado: (2023)

519. Early Transition to Outpatient Remdesivir Increases Patient Satisfaction while Decreasing Hospital Costs
por: Chesdachai, Supavit, et al.
Publicado: (2023)

557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients
por: Arribas, Jose Ramon, et al.
Publicado: (2020)

73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir
por: Diaz, George, et al.
Publicado: (2020)

Compassionate Use of Remdesivir for Patients with Severe Covid-19
por: Grein, Jonathan, et al.
Publicado: (2020)

Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019
por: Burwick, Richard M, et al.
Publicado: (2020)

Remdesivir-associated bradycardia in COVID-19: a rapid review protocol
por: Tian, Elli, et al.
Publicado: (2023)

Remdesivir in Breastfeeding
por: Sadati, Elham, et al.
Publicado: (2022)

Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study
por: Rajme-López, Sandra, et al.
Publicado: (2022)

Remdesivir: Infusion site reaction following extravasation of remdesivir: case report
Publicado: (2021)

Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience
por: Tiseo, Giusy, et al.
Publicado: (2022)

Patients’ and clinicians’ experiences of the DSM-5 Cultural Formulation Interview: A mixed method study in a Swedish outpatient setting
por: Wallin, Malin Idar, et al.
Publicado: (2020)

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
por: Olender, Susan A, et al.
Publicado: (2021)

Remdesivir: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Remdesivir for COVID-19
Publicado: (2020)

Remdesivir and COVID-19
por: Glaus, Matthew J, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Wang, Lei-Yun, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Dennis, Alicia
Publicado: (2020)

Remdesivir and COVID-19
por: Edwards, Jessie K, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g4r5kfhka4185ddk5thn62q814